Study S002709

An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to GLP-1 Analogue in Subjects With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02227849
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 71
Start: 2014-08
Primary completion: 2016-03
Lead sponsor: Tanabe Pharma Corporation
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Canagliflozin (TA-7284); DRUG:GLP-1 analogue
Results posted: TRUE

Registered primary outcomes

Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events) [52 Weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006955	Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study. Harashima SI, Diabetes, obesity & metabolism	2018	Other trial	PMID 29473709 DOI	registry reference RESULT:29473709